Key result
Despite consensus that ICD deactivation should be routinely discussed in end-stage heart failure, this rarely occurs in clinical practice due to uncertainty and reluctance to confront death.
Despite consensus on the need for routine discussion of ICD deactivation in end-stage heart failure, it rarely occurs in clinical practice due to uncertainty and reluctance to confront death.
Answers are grounded in this paper and cite their sources.
Gap persists between consensus and ICD deactivation discussions in end-stage HF; leaves open effective strategies to address clinician barriers.
Implantable cardioverter defibrillators (ICDs) reduce mortality in selected patients with chronic heart failure but prognostic benefit is likely to attenuate with progression to end-stage heart failure. The incidence of multiple futile ICD shocks before death is uncertain. Only individual patients, supported by their healthcare professionals, can decide when ICD therapy becomes futile in end-stage heart failure. Despite consensus that ICD deactivation should be routinely discussed, this rarely occurs in clinical practice for many reasons including uncertainty about when to initiate these discussions and reluctance to confront death and dying. Patient and carer opinions about end-stage heart failure and ICD deactivation may not meet professional expectations. Future research should focus on these opinions and examine interventions that bridge the gap between best practice and the reality of current clinical practice.
No takes yet. Share an insight, caveat, or question.
Pettit et al. (2012) conducted a review in End-stage heart failure. Implantable cardioverter defibrillators (ICDs) was evaluated. Despite consensus that ICD deactivation should be routinely discussed in end-stage heart failure, this rarely occurs in clinical practice due to uncertainty and reluctance to confront death.
Synapse has enriched 10 related papers. Consider them for comparative context: